00:00Let's bring in Novo Nordis Chief Scientific Officer Martin Hoslong on this.
00:05Martin, thank you so much for joining us this morning.
00:07And I just want to bring you a comment from a shareholder of Novo Nordis, of Global Health Invest.
00:13Novo Nordis' opportunity to make a comeback in the fight against Lilly, this was it.
00:18This obviously weakens them in a fight.
00:20What would be your message to those who believe the same thing, who have looked at this study and said,
00:25now this means Novo is falling even further behind Eli Lilly?
00:30I would answer it's been a few years since we designed the redefined program,
00:36the program to show the weight loss potential of kagosemma.
00:41We already last year learned that to really see the true weight loss potential of kagosemma,
00:47it is a very powerful combination of two molecules.
00:51We need to have what we call a bespoke titration algorithm to really allow patients to titrate
00:57the very powerful treatment in the way that they prefer.
01:01We could see from the first study that that could be further optimized.
01:06In this setting, we could not manage to implement those learnings in what we call redefined form,
01:12which is the study that we discussed today.
01:15So the jury is still out of what can kagosemma actually achieve.
01:20In the study that read out today, we saw 23 percent weight loss with kagosemma.
01:25That is actually very substantial.
01:28And it is among the best weight losses that we've seen, also amongst drugs in the market.
01:34Right.
01:35Of course, just sort of the sore point in that, if I can jump in, Martin, is just the comparison
01:40to Lily.
01:41It will forever be there.
01:42So what is the plan then to catch up with them?
01:45Yeah, exactly.
01:46So first of all, the 23 percent weight loss that we saw with kagosemma is in line with what we've
01:52previously seen.
01:53The 25 percent, which we saw with the comparative drug, is actually the best data that has been seen so
02:00far in similar trials,
02:01which is a little bit surprising, but it stands alone in terms of that 25 percent.
02:09But we've also taken a lot of learnings in terms of how we can improve the titration for kagosemma.
02:15We've implemented those learnings in a study that's currently ongoing.
02:19That study is called Redefine 11.
02:21And we've got it for the last year that only when we see those data do we know the full
02:26weight loss potential of kagosemma.
02:28Furthermore, we are initiating during this year phase three studies to investigate even higher doses of kagosemma.
02:37And then obviously we have our very competitive pipeline starting with Senegemta that starts phase three this year,
02:44but also our two triagonists that is currently in phases one and two.
02:48So I think from a short but also a longer term perspective, we have a very competitive portfolio and pipeline.
02:55Martin, on that pipeline, you seem confident on it.
02:58Would you like to see that bolstered by some M&A by bringing inorganic growth to the pipeline too?
03:05The way we think about this is that obesity is a very complex disease and obviously we want to have
03:11drugs that provide the biggest weight loss.
03:13But we also want to have drugs that gives as few side effects as possible.
03:18We also want to have drugs that provide comorbidities.
03:21And to an extent in our current portfolio, we have all of that.
03:25We also have the best-in-class oil already on the market in the U.S.
03:32And the Senegemtide offering that is starting phase three will have both a subcutaneous and an oil offering with what
03:41we believe will be best-in-class.
03:43Martin, why within that did you not follow Lilly with the Terzepratide and develop a GLP-1, GIP?
03:48Why not go down that route when so many other companies did?
03:53We need to follow our philosophy when we do development.
03:58We always want to see differentiated weight loss potential or efficacy potential, but also differentiated safety and tolerability.
04:05We do believe that we will see that when we see Redefined 11 in terms of weight loss with Kagosema.
04:13But we also believe that we have that potential for amicretin, which is another version of addressing two biologies.
04:22So you mentioned GLP-1, GIP.
04:26Senegemtide is GLP-1 plus amlin.
04:32And then we have what we call triagonist, which is basically the next level.
04:37We do again believe that that is going to be a very competitive offering individually, but specifically as a portfolio.
Comments